The Top 5 Biosimilar Articles for the Week of July 26

Here are the top 5 biosimilar articles for the week of July 26, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of July 26, 2021.

Number 5: Biosimilar uptake could be more robust in the United States if the FDA can be convinced that biosimilars are worth the effort, said Rep Kurt Schrader, D-Oregon.

Number 4: Shanghai Henlius Biotech initiated a trial for patients with macular degeneration while Dong-A ST and Meiji Seika Pharma agreed on a distribution plan for a ustekinumab biosimilar candidate.

Number 3: Biocon reported on its revenues from biosimilars and the FDA status of its insulin glargine product.

Number 2: The Biologics Price Competition and Innovation Act (BPCIA) provides a stepwise approach for fact-finding prior to patent litigation, but companies may choose their own path, case examples showed.

Number 1: Without disclosing terms, Pfizer said it settled with Johnson & Johnson (J&J) over a long-running dispute in which J&J was alleged to have blocked payers from covering Inflectra.

To read all of these articles and more, visit centerforbiosimilars.com.